Terms: = Pancreatic cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Clinical Outcome
4 results:
1. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
[TBL] [Abstract] [Full Text] [Related]
2. clinical implications of microsatellite instability and mlh1 gene inactivation in sporadic insulinomas.
Mei M; Deng D; Liu TH; Sang XT; Lu X; Xiang HD; Zhou J; Wu H; Yang Y; Chen J; Lu CM; Chen YJ
J Clin Endocrinol Metab; 2009 Sep; 94(9):3448-57. PubMed ID: 19567531
[TBL] [Abstract] [Full Text] [Related]
3. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.
Dong X; Jiao L; Li Y; Evans DB; Wang H; Hess KR; Abbruzzese JL; Li D
J Clin Oncol; 2009 Apr; 27(10):1592-9. PubMed ID: 19237629
[TBL] [Abstract] [Full Text] [Related]
4. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis.
Sedivy R; Kalipciyan M; Mazal PR; Wolf B; Wrba F; Karner-Hanusch J; Mühlbacher F; Mader RM
Cancer Detect Prev; 2005; 29(1):8-14. PubMed ID: 15734212
[TBL] [Abstract] [Full Text] [Related]